- Home
- SNTI
as 07-26-2024 4:00pm EST
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with their gene circuit platform technologies to fight challenging diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 15.6M | IPO Year: | N/A |
| Target Price: | $60.00 | AVG Volume (30 days): | 2.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -14.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.11 - $10.90 | Next Earning Date: | 08-09-2024 |
| Revenue: | $1,275,000 | Revenue Growth: | -71.47% |
| Revenue Growth (this year): | 254.47% | Revenue Growth (next year): | 169.66% |
Latest Senti Biosciences Inc. News
SNTI Breaking Stock News: Dive into SNTI Ticker-Specific Updates for Smart Investing
MT Newswires
10 days ago
Senti Biosciences Board Authorizes 1-for-10 Reverse Stock Split; Shares Fall
GlobeNewswire
11 days ago
Senti Bio Announces Reverse Stock Split
MT Newswires
25 days ago
Top Midday Gainers
GlobeNewswire
a month ago
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy
GlobeNewswire
2 months ago
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
GlobeNewswire
3 months ago
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights
GlobeNewswire
3 months ago
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
GlobeNewswire
4 months ago
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights
Compare SNTI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SNTI Senti Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.